3,3′-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1669-1673

  Kim, Seo Ju ^a   Lee, Ju Seog ^b   Kim, Soo Mi ^a  

^a Chonbuk National University Medical School   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

3,3 diindolylmethane; Apoptosis; G1 arrest; Human esophageal squamous carcinoma cells

Indexed keywords

3,3' DIINDOLYLMETHANE; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P15; PROTEIN P27; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; INDOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECT; ESOPHAGUS TUMOR; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; INDOLES;

EID: 84863281650     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1662     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Incarbone R, Bonavina L, Saino G, Bona D and Peracchia A: Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 16: 263-266, 2002. (Pubitemid 34112973)
3. Wolf MC, Stahl M, Krause BJ, et al: Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol 6: 55, 2011.
4. Kim SM, Park YY, Park ES, et al: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5: e15074, 2010.
5. Fukuzawa K, Noguchi Y, Yoshikawa T, et al: High incidence of synchronous cancer of the oral cavity and the upper gastrointestinal tract. Cancer Lett 144: 145-151, 1999. (Pubitemid 29457656)
6. Siewert JR, Feith M and Stein HJ: Esophagectomy as therapeutic principle for squamous cell esophageal cancer. Chirurg 76: 1033-1043, 2005 (In German). (Pubitemid 41639857)
7. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H and Fink U: Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234: 360-369, 2001. (Pubitemid 32847073)
8. Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M and Siewert JR: Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 242: 566-575, 2005. (Pubitemid 41428652)
9. Verhoeven DT, Verhagen H, Goldbohm RA, van den Brandt PA and van Poppel G: A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Chem Biol Interact 103: 79-129, 1997. (Pubitemid 27081513)
10. Verhoeven DT, Goldbohm RA, van Poppel G, Verhagen H and van den Brandt PA: Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev 5: 733-748, 1996. (Pubitemid 26304649)
11. Kim EJ, Park SY, Shin HK, Kwon DY, Surh YJ and Park JH: Activation of caspase-8 contributes to 3,3′-diindolylmethane-induced apoptosis in colon cancer cells. J Nutr 137: 31-36, 2007.
12. Wattenberg LW and Loub WD: Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 38: 1410-1413, 1978. (Pubitemid 8323347)
13. Chen I, McDougal A, Wang F and Safe S: Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19: 1631-1639, 1998. (Pubitemid 28441867)
14. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is potentiated by 3,3′- diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 7: 1708-1719, 2008.
15. Chinnakannu K, Chen D, Li Y, et al: Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol 219: 94-99, 2009.
16. Bhuiyan MM, Li Y, Banerjee S, et al: Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66: 10064-10072, 2006. (Pubitemid 44672060)
17. Kong D, Banerjee S, Huang W, et al: Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68: 1927-1934, 2008. (Pubitemid 351416579)
18. Li Y, Chinni SR and Sarkar FH: Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10: 236-243, 2005. (Pubitemid 40543031)
19. Nachshon-Kedmi M, Fares FA and Yannai S: Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 61: 153-160, 2004. (Pubitemid 39244702)
20. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65: 364-371, 2005.
21. Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S: 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 27: 717-728, 2006.
22. Carter TH, Liu K, Ralph W Jr, et al: Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr 132: 3314-3324, 2002. (Pubitemid 35304238)
23. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM and Sarkar FH: Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3-diindolylmethane (DIM). Pharm Res 25: 2117-2124, 2008.
24. Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol 39: 1587-1591, 2011.
25. Reed GA, Arneson DW, Putnam WC, et al: Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′-diindolylmethane. Cancer Epidemiol Biomarkers Prev 15: 2477-2481, 2006. (Pubitemid 46048308)
26. Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69: 5592-5600, 2009.
27. Zhang J, Hsu BAJ, Kinseth BAM, Bjeldanes LF and Firestone GL: Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer 98: 2511-2520, 2003. (Pubitemid 37466668)
28. Aggarwal BB and Ichikawa H: Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4: 1201-1215, 2005. (Pubitemid 41365390)
29. Kong D, Li Y, Wang Z, Banerjee S and Sarkar FH: Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67: 3310-3319, 2007. (Pubitemid 46724870)
30. Li Y, Wang Z, Kong D, et al: Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282: 21542-21550, 2007. (Pubitemid 47099972)
31. Vivar OI, Lin CL, Firestone GL and Bjeldanes LF: 3,3′-Diindo- lylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem Pharmacol 78: 469-476, 2009.
32. Choi HJ, Lim do Y and Park JH: Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 9: 39, 2009.
33. Cho HJ, Park SY, Kim EJ, Kim JK and Park JH: 3,3′-Diindo- lylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. Mol Carcinog 50: 100-112, 2011.
34. Hong C, Kim HA, Firestone GL and Bjeldanes LF: 3,3′-Diindo- lylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 23: 1297-1305, 2002.
35. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408-9421, 2005.
36. Maddika S, Ande SR, Panigrahi S, et al: Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10: 13-29, 2007. (Pubitemid 46636381)
37. Koff A, Cross F, Fisher A, et al: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228, 1991. (Pubitemid 121001411)
38. Dobashi Y: Cell cycle regulation and its aberrations in human lung carcinoma. Pathol Int 55: 95-105, 2005.